pu-h71
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 26, 2011 (NCT01581541)
Timeline
Indications
Mechanism of action
HSP90AB2P inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)NCCCn1c(Sc2cc3c(cc2I)OCO3)nc2c(N)ncnc21- Mol. weight
- 512.38 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL200102 ↗
Also known as
- 9h-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-n-(1-methylethyl)-
- pu h71
- pu-h71
- pu-h71
- pu-h71
- pu-h71
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05612633 | Phase 2 | Jun 15, 2022 | Samus Therapeutics |
| NCT03935555 | Phase 1 | May 1, 2019 | Samus Therapeutics |
| NCT03373877 | Phase 1 | May 24, 2018 | Samus Therapeutics, Sponsor GmbH |
| NCT03166085 | Phase 1 | May 23, 2017 | Cornell University, Samus Therapeutics |
| NCT01393509 | Phase 1 | Jul 1, 2011 | Cornell University |
| NCT01581541 | Phase 1 | Apr 26, 2011 | National Cancer Institute (NCI) |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Samus Therapeutics | For profit | 4 | 3 | 2 | 2017 |
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2011 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1